Antitumor activity of 3'-deamino-3/-morpholino anthracyclines was examined. Morpholino derivatives of 13-deoxocarminomycins, MX2(1), MX(2) and MY5 (3) shown in Fig. 1 , administered iv showed increase in life span (ILS) values over 110% against ip-inoculated P388 leukemia. The ranges of effective doses of these compoundswere broader than those of their parent drugs. The morpholino derivatives of doxorubicin and carminomycin, however, were not so effective as their parent drugs. Amongthese compounds, MX2 administered orally showednearly the same effects as those obtained by iv administration against P388 leukemia. MX2administered iv showed 89 % ILS against intracerebrally-inoculated L1210 leukemia. The highly lipophilic nature of MX2could contribute partly to achieving chemotherapeutic responses against intracerebrally-inoculated tumors or by oral administration.
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Five morpholino anthracyclines : MX2(1), MX(2), MY5(3)x), S'-deamino-S'-morpholinocarminomycin (4)2) and S'-deamino-S'-morpholinoadriamycin (5)2) were prepared by iV-alkylation of 1 3-deoxo-10-hydroxycarminomycin (oxaunomycin) (6)3), 13-deoxocarminomycin (7)4), 13-deoxo-l1-deoxycarminomycin (8)5), carminomycin (9) and doxorubicin (10), respectively. The present study investigates the effect of these morpholino anthracyclines on murine tumor models including a brain tumor model, and compares these effects with those of their parent drugs.
Materials and Methods

Drugs
The following compounds were prepared in our laboratory: MX2 (1); MX (2); MY5 (3); 3' -deamino-S' -morpholinocarminomycin (4) ; 3/-deamino-3/-morpholinoadriamycin (5); 13-deoxo-10-hydroxycarminomycin (6); 13-deoxocarminomycin (7); 13-deoxo-l1-deoxycarminomycin (8) and carminomycin (9). Doxorubicin (10) formulated for clinical use was the product of KyowaHakko Kogyo Co., Ltd., Tokyo, Japan. Tumorsand Animals P388 leukemia and L1210 leukemia were obtained from the NCI, NIH, U.S.A., and were maintained by the Cancer Chemotherapy Center, Tokyo, Japan. Mice were supplied by the Shizuoka Laboratory Animal Center, Hamamatsu, Japan. Six to 8 weeks old female CDFX(BALB/c XDBA/2) mice were used. One-tenth ml of cell suspension in phosphate-buffered saline (PBS) containing 10s P388 leukemia cells was inoculated ip into mice. In another experiment, 5 [A of cell suspension in PBS containing 104 L1210 leukemia cells was inoculated intracerebrally (ic) into mice. Drugs were administered ip, iv or po at a constant rate of 0.01 ml/g body weight.
From the mean survival times of the treated (T) and the control (C) mice, the increase in life span |(ILS=(T/C-1) x 100%) was calculated. Tumor-free survivors were excluded from the calculation. Determination of MX2in Brain Tissue MX2was intravenously administered to male SD rats. After 2 or 8 hours, the whole brain was excised, and homogenized. MX2was extracted from the homogenate with CHC13-MeOH (4 : 1) separated by reversed phase HPLCand detected fiuorimetrically.
Log P Measurement
Drugs were partitioned between 1-octanol and 100 mMphosphate buffer (pH 7.4). The concentration of the drug in each phase was determined by reversed phase HPLCequipped with a UV absorption detector. Log P was calculated from the equation ; log P =log (concentration in an organic phase/concentration in an aqueous phase).
Results
The Antitumor Activity of Morpholino Anthracyclines and their Parent Drugs against P388 Leukemia The antitumor activity of the drugs administered iv against ip-inoculated P388 leukemia on days 1 and 5 was examined (Figs. 2 and 3) . MX2, MXand MY5showed 140, 111 and 142% ILS at doses of 3.33, 6.67 and 60 mg/kg, respectively.
MX2, MXand MY5required 1.7 to 3.8 times higher doses Toxic: Drugadministration was discontinued because of toxicity.
to produce the maximumILS's as compared to their parent drugs. The effective dose ranges of MX2, MXand MY5were broader than those of their parent drugs. On the other hand, morpholino carminomycinand morpholino doxorubicin required lower doses to produce maximumILS's as compared to their parent drugs, and the effective dose ranges were narrower than those of their parent drugs.
The Dosing Schedule Dependence of the Activity of Morpholino Anthracyclines
The antitumor activity of MX2administered iv against P388 leukemia on day 1, days 1 and 5, O iv. Ado.
P388 leukemia cells (106/mouse) were inoculated ip on day 0. MX2was administered iv.
Toxic: Drug administration was discontinued because of toxicity.
P388 leukemia cells (106/mouse) were inoculated ip on day 0. MX2was administered on days 1, 5 and9. days 1, 5 and 9 or days 1 to 9 was examined (Fig. 4) . MX2induced remarkable prolongation of the life span in parallel with the extension of the effective dose range either by days 1 and 5 or days 1, 5 and 9 administration though it induced a less prolonged life span accompanied with a less extended effective dose range by day 1 or days 1 to 9 administration. MXand MY5were also more effective by days 1 and 5 or days 1, 5 and 9 administration than the other schedules (data not shown). Therefore the drugs were administered on days 1, 5 and 9 in the following experiments.
The Antitumor Activity of po Administered Morpholino Anthracycline The antitumor activity of MX2administered po against P388 leukemia on days 1, 5 and 9 was examined (Fig. 5) . The maximumtolerated dose (3.33 mg/kg) of MX2by po administration was equal to that by iv administration, and a maximumILS of 175%was obtained. MXand MY5were also effective by po administration (data not shown).
The Antitumor Activity of Morpholino Anthracyclines against ic-Inoculated L1210 Leukemia Since MX2was effective by po administration and its log P value was as muchas 2.84, the effect of MX2on a brain tumor model was tested, expecting that MX2would potentially pass blood-brain barrier. MX2showed maximum ILS of 89% at 3 mg/kg by days 1, 5 and 9 iv administration.
However the parent compound 13-deoxo-10-hydroxycarminomycin showed marginal activity in the dose range of 0.25 to 2 mg/kg (Table 1) . LI210 leukemia cells (104/mouse) were inoculated ic on day 0. The drugs were administered on days 1, 5 and 9.
Concentration of MX2in Brain Tissue The concentrations of MX2in brain tissue 2 and 8 hours after iv administration of 2 mg/kg MX2 were 0.25 and 0.02^g/g tissue, respectively.
LogP
Log P values of MX2, doxorubicin and aclarubicin were 2.84, -0.032 and 3.20, respectively.
Discussion
It has been known that the antitumor activity of anthracycline derivatives alters dramatically by cyclo-alkylation at N-3' position in its daunosamine residue into morpholino derivatives^. In our results, it is clear that the antitumor potency of the derivatives of 13-deoxocarminomycin is reduced by the alkylation so that high doses are required to produce the activity similar to that of parent compounds, however, the effective dose ranges are broadened. Administration of the morpholino derivatives on days 1, 5 and 9 induced the most effective effect against P388 leukemia among the administration schedule tested. Therefore days 1, 5 and 9 administration was adopted in the later experiments. MX2shows nearly equal activity by po administration as that obtained by iv administration, suggesting that MX2could readily be absorbed into the gastro-intestinal tract. In addition, MX2ad-ministered systemically through the iv route exerts an antitumor effect on ic-inoculated L1210leukemia, indicating that this compound passes the blood-brain barrier. Existence of MX2in the cerebrum after iv injection of MX2was confirmed by HPLC. The lipophilicity of MX2might contribute to the absorption and the penetration of the drug, however, it was not the sole determinant because morpholino doxorubicin, cyanomorpholino doxorubicin7) and aclarubicin which have comparable log P values were not active against ic-inoculated LI210 leukemia (data not shown).
